1. Clinical trial considerations on male contracption and collection of pregnancy information from female partners;Banholzer;J. Transl. Med.,2012
2. Clinical Trial Facilitation Group, Recommendations related to contraception and pregnancy testing in clinical trials, Advisory non-binding guidance supported by national competent authorities, Rome 2014-09-152014, http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf.
3. U.S.F.D.A., Assessment of male-mediated developmental risk for pharmaceuticals: guidance for industry, Draft guidance. U.S. Department of Health and Human Services, 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM450627.pdf.
4. The transport of chemicals in semen;Klemmt;Birth Defects Res. B,2005
5. Introduction to the HESI DART drugs in semen consortium;Chen;Reprod. Toxicol.,2014